Deltex Medical Group plc AGM 28 April 2011 Ewan Phillips

Introduction World leader in ODM Intervene – fluid during surgery Monitor – cardiac output in critical care Simple – to learn, to use & very safe Evidence – robust: clinical & economic Implementation Bottom-up – hospital level by procedure Top-down – system level standard of care World leader in ODM Intervene – fluid during surgery Monitor – cardiac output in critical care Simple – to learn, to use & very safe Evidence – robust: clinical & economic Implementation Bottom-up – hospital level by procedure Top-down – system level standard of care

Sales growing Fastest growth in surgery in UK & US High margins 74% overall >80% in direct markets Stable cost base Cash positive in second half

Financial Highlights - Cash

NICE guidance Important validation Positive recommendation for surgery Reduce post-operative complications Reduce cost by circa £1,100 per patient Major and high risk surgery Over 800,000 NHS patients a year “Dominant” technology Still need change in practice and NHS cash

£20 billion savings target Innovative Technologies Adoption Procurement Programme National Technology Adoption Centre support Enhanced recovery – national roll-out NICE evaluation pathway Issued 30 March Product specific Extra income for NHS hospitals under CQUIN Oesophageal Doppler specific Enhanced recovery

International growth strategy US Strategy Demonstration ‘stories’ from existing accounts Stand-alone improvement & enhanced recovery Targeting hospital groupings with ‘quality’ agendas Quality indicator for surgery International Strategy Build on Paris tender in France Support Spanish projects to conclusions ‘Exporting’ NICE, NTAC, CQUIN, enhanced recovery

ODM solves a major clinical problem ODM implementable: Stand-alone change in practice Enhanced recovery surgical programmes Evidence key to system wide adoption NICE guidance is important validation Growth rates encouraging Potential for considerable acceleration